Foghorn Therapeutics Inc.
NASDAQ:FHTX

Watchlist Manager
Foghorn Therapeutics Inc. Logo
Foghorn Therapeutics Inc.
NASDAQ:FHTX
Watchlist
Price: 4.48 USD 0.67% Market Closed
Market Cap: 253.3m USD

Wall Street
Price Targets

FHTX Price Targets Summary
Foghorn Therapeutics Inc.

Wall Street analysts forecast FHTX stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for FHTX is 11.95 USD with a low forecast of 9.09 USD and a high forecast of 14.7 USD.

Lowest
Price Target
9.09 USD
103% Upside
Average
Price Target
11.95 USD
167% Upside
Highest
Price Target
14.7 USD
228% Upside
Foghorn Therapeutics Inc. Competitors:
Price Targets
002675
Yantai Dongcheng Biochemicals Co Ltd
27% Upside
ADMA
ADMA Biologics Inc
36% Upside
600161
Beijing Tiantan Biological Products Corp Ltd
48% Upside
MDGL
Madrigal Pharmaceuticals Inc
0% Upside
GBIO
Generation Bio Co
474% Upside
ALT
Altimmune Inc
254% Upside

Revenue
Forecast

Revenue Estimate
Foghorn Therapeutics Inc.

The compound annual growth rate of Foghorn Therapeutics Inc.'s revenue for the next 3 years is 21%.

N/A
Past Growth
21%
Estimated Growth
Estimates Accuracy
-28%
Average Miss

Operating Income
Forecast

Operating Income Estimate
Foghorn Therapeutics Inc.

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
2%
Average Beat

Net Income
Forecast

Net Income Estimate
Foghorn Therapeutics Inc.

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-26%
Average Miss
Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.

What is FHTX's stock price target?
Price Target
11.95 USD

According to Wall Street analysts, the average 1-year price target for FHTX is 11.95 USD with a low forecast of 9.09 USD and a high forecast of 14.7 USD.

What is Foghorn Therapeutics Inc.'s Revenue forecast?
Projected CAGR
21%

The compound annual growth rate of Foghorn Therapeutics Inc.'s revenue for the next 3 years is 21%.

Back to Top